openPR Logo
Press release

Osteoporosis Drugs Global Market is Projected to Increase Revenues Growth, Business Insights, Future Demand and Forecast 2024-2033 | Pfizer Inc., Novartis AG, Viatris Inc., Cipla Limited, Recordati S.p.A.

07-15-2024 12:15 PM CET | Health & Medicine

Press release from: The Business research company

Osteoporosis Drugs Market

Osteoporosis Drugs Market

"The new report published by The Business Research Company, titled ""Osteoporosis Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the osteoporosis drugs market size has grown steadily in recent years. It will grow from $12 billion in 2023 to $12.48 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9102&type=smp

Rising Prevalence Of Osteoporosis Fuels Growth In The Osteoporosis Drug Market
A surge in the prevalence of osteoporosis is expected to propel the growth of the osteoporosis drug market. Osteoporosis is a bone disease that occurs when bone mineral density and mass bone decline or when bone quality or structure changes. People who have a low calcium intake are more likely to develop osteoporosis. These osteoporosis drugs increase bone mineral density and help to prevent fractures. For instance, In May 2022, according to statistics published by Amgen, a US-based biotechnology company, states that every year, osteoporosis causes roughly 1.5 million fractures in the United States, resulting in $19 billion in associated costs. Furthermore, the annual number of fractures caused by osteoporosis is expected to rise by 68% from 2018 to 2040, i.e., from 1.9 million to 3.2 million. Therefore, the surging prevalence of osteoporosis is driving the growth of the osteoporosis drugs market.

Innovative Solutions In Osteoporosis Treatment With Teriparatide Injectable For Affordable And Convenient Patient Care
Major companies operating in the osteoporosis drugs market are advancing toward the use of innovative solutions for the osteoporosis drug market. For instance, in November 2023, Apotex Inc., a Canada-based pharmaceutical corporation, launched Teriparatide Injectable for Osteoporosis Treatment. Injection of teriparatide is a pre-filled pen containing 250 mcg/mL, capable of administering 28 daily doses of 20 mcg per pen, intended for single-patient use. This product will give these patients much-needed, reasonably priced access.

The osteoporosis drugs market covered in this report is segmented -
1) By Type: Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors
2) By Administration: Oral, Injectable
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Sales
4) By Application: Primary Osteoporosis, Secondary Osteoporosis

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9102&type=discount

Major companies operating in the osteoporosis drugs market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Daiichi Sankyo Company Limited, Union Chimique Belge, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Enzene Biosciences Ltd, Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Ligand Pharmaceuticals Incorporated, Theramex, Radius Health Inc., Actavis PLC, Strides Pharma Science Limited, Apotex Inc.

Contents of the report:
1. Executive Summary
2. Osteoporosis Drugs Market Report Structure
3. Osteoporosis Drugs Market Trends And Strategies
4. Osteoporosis Drugs Market - Macro Economic Scenario
5. Osteoporosis Drugs Market Size And Growth
…..
27. Osteoporosis Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Osteoporosis Drugs Global Market is Projected to Increase Revenues Growth, Business Insights, Future Demand and Forecast 2024-2033 | Pfizer Inc., Novartis AG, Viatris Inc., Cipla Limited, Recordati S.p.A. here

News-ID: 3580952 • Views:

More Releases from The Business research company

Leadless Pacemakers Market on Track for Strong Growth, Estimated to Grow at 14.8% CAGR Through 2029
Leadless Pacemakers Market on Track for Strong Growth, Estimated to Grow at 14.8 …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Leadless Pacemakers Market Through 2025? The global market for pacemakers without leads has experienced substantial recent expansion, projected to increase from $0.58 billion in 2024 to reach $0.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 15.0%; this upward
Emerging Trends to Reshape the Global Irradiation Sterilization Services Market: Innovative Intelligent UVC Disinfection Technology Solutions Transform Irradiation Sterilization Services Market as a Key Influencer
Emerging Trends to Reshape the Global Irradiation Sterilization Services Market: …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Irradiation Sterilization Services Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The sphere of irradiation sterilization services has experienced swift expansion lately, progressing from a valuation of $2.65 billion in 2024 to an anticipated $3.01 billion in 2025, thereby reflecting a compound annual growth rate
Future of the Global Hyperimmune Globulins Market: Drivers, Innovations, and Key Forecasts Through 2034
Future of the Global Hyperimmune Globulins Market: Drivers, Innovations, and Key …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Hyperimmune Globulins Market Size Growth Forecast: What to Expect by 2025? The global market for hyperimmune globulins has demonstrated robust expansion lately, projected to ascend from a valuation of $1.91 billion in 2024 to $2.06 billion the following year, reflecting a compound annual growth rate (CAGR) of 7.5 percent,
Key Factor Supporting Global Histone Deacetylase (HDAC) Inhibitors Market Development in 2025: Rising Neurodegenerative Disorders Drive Growth In HDAC Inhibitors Market
Key Factor Supporting Global Histone Deacetylase (HDAC) Inhibitors Market Develo …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Histone Deacetylase (HDAC) Inhibitors Market Size By 2025? The valuation of the histone deacetylase (hdac) inhibitors market has seen considerable expansion lately, projected to advance from $1.23 billion in 2024 to reach $1.32 billion by 2025, reflecting a consistent annual growth rate of 7.6% over

All 5 Releases


More Releases for Osteoporosis

Rising Prevalence Of Osteoporosis Fuels Growth In Osteoporosis Treatment Market: …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Osteoporosis Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025? In the realm of osteoporosis treatments, the market has seen consistent expansion recently, projected to increase its valuation from $13.96 billion in 2024 to $14.57 billion come 2025, reflecting a compound annual growth rate of
Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Postmenopausal Osteoporosis Treatment Market Through 2025? Valuations for the marketplace addressing postmenopausal osteoporosis treatments have demonstrated consistent upward movement throughout the preceding years, projecting an expansion from a figure of $10.1 billion in 2024 to an anticipated $10.54 billion by 2025, reflecting
Rising Prevalence Of Osteoporosis Fuels Growth In The Osteoporosis Drug Market: …
The Osteoporosis Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Osteoporosis Drugs Market Size During the Forecast Period? The market for medications for osteoporosis has seen a consistent rise in recent years. The current market value of $12.33 billion in 2024
Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis …
The Postmenopausal Osteoporosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Postmenopausal Osteoporosis Treatment Market Size and Its Estimated Growth Rate? The market for treatment of postmenopausal osteoporosis has seen a steady increase in size over the recent years. It's projected
Osteoporosis Drug Market, By Type (Primary Osteoporosis and Secondary Osteoporos …
Osteoporosis is a condition of bone weakening or bones becomes fragile and likely to break. In other words, osteoporosis is a condition wherein the bone density decreases. This is specially witnessed in old age people. Osteoporosis brings along back pain, stooped posture, bone fracture and tooth loss. View Detailed Report" https://www.databridgemarketresearch.com/reports/global-osteoporosis-drug-market The global osteoporosis drug market is experiencing steady growth driven by factors such as the increasing aging population, rising prevalence of
Osteoporosis Drugs Market: Demand for Osteoporosis Drugs High Among Geriatric Po …
The global osteoporosis drugs market is analyzed in a report by Transparency Market Research (TMR). The market is expected to grow due to the increasing geriatric population across the globe. The market for osteoporosis drugs is considered semi-consolidated as a handful of players hold a larger share in the market. As per the analysis, Novartis International AG, Eli Lilly and Company, Merck & Co. Inc., Pfizer Inc., and Amgen Inc.